Validity of Continuous Metabolic Syndrome Score for Predicting Metabolic Syndrome; a Systematic Review and Meta-Analysis Publisher



Khazdouz M¹ ; Hasani M¹ ; Mehranfar S² ; Ejtahed HS^{3, 4} ; Djalalinia S^{5, 6} ; Mahdavi Gorabi A⁷ ; Esmaeiliabdar M⁸ ; Karbalahi Saleh S⁹ ; Arzaghi SM¹⁰ ; Zahedi H¹¹ ; Kasaeian A^{12, 13, 14} ; Qorbani M^{15, 16}
Source: Journal of Diabetes and Metabolic Disorders Published:2021

Abstract

Background: Nowadays, use of continuous metabolic syndrome (cMetS) score has been suggested to improve recognition of metabolic syndrome (MetS). The aim of this study was to evaluate the validity of cMetS scores for predicting MetS. Methods: We searched the electronic databases included MEDLINE/PubMed, Embase, ISI Web of Science, and Scopus from 1 January 1980 to 30 September 2020. Observational studies on participants with different cMetS scores were included in this meta-analysis. The sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR) and diagnostic odds ratio (DOR) with 95% CI were calculated. Results: Ten studies involving a total of 25,073 participants were included. All studies had cross-sectional design. The pooled sensitivity and specificity of cMetS scores for predicting MetS were 0.90 (95% CI: 0.83 to 0.95) and 0.86 (95% CI: 0.83 to 0.89), respectively. Moreover, cMetS scores had the pooled LR+ of 6.5 (95% CI: 5.0 to 8.6), and a pooled (LR-) of 0.11 (95% CI: 0.063 to 0.21). The pooled DOR of cMetS scores to predict MetS were 57 (95% CI: 26 to 127). Conclusions: The high sensitivity and specificity of cMetS scores indicates that it has a high accuracy to predict the risk of MetS. Furthermore, the cMetS scores has a good ability to rule out healthy people. Study registration: This study was registered as PROSPERO CRD42020157273. © 2021, Springer Nature Switzerland AG.